Abbott’s 14-day Freestyle Libre continuous glucose monitor (CGM) has been approved by the FDA, giving US patients with diabetes access to technology that has been used in Europe for years.

The FDA has granted clearance for a standalone reader for the Abbott FreeStyle Libre 3 CGM. The reader uses a rechargeable lithium-ion battery similar to what is used in other electronic devices ...

The FreeStyle Libre is a continuous glucose monitoring (CGM) system that doesn’t require a blood sample from a finger stick. It’s manufactured by Abbott, a company that produces other diabetes ...

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before. Read why ABT stock is a Buy.

The FreeStyle Libre system consists of a glucose sensor inserted into the back of the upper arm for up to 14 days and a scanner that users wave over the sensor to obtain readings. Like a ...

Abbott Laboratories ABT recently received the approval from Health Canada for its next-generation FreeStyle Libre 2 system for diabetics above the age of four. The regulatory approval makes the ...

The Freestyle Libre is one brand of CGM technology that is covered in some cases by Medicare. CGMs have been covered by Medicare for some time under Medicare Part B.

The FDA classified Thursday a recent product recall by Abbott Laboratories (ABT) for ts FreeStyle Libre glucose monitoring systems as a Class I recall. Read more here.

The US Food and Drug Administration (FDA) has cleared the FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system for adults and children ages 4 years and older with diabetes.

The FDA has approved Abbott’s FreeStyle Libre Pro continuous glucose monitoring system for clinicians to use with diabetic patients.